SKL1223

Overview

SKL1223 is an orally effective thioredoxin-interacting protein ( TXNIP ) inhibitor with an IC 50 of 0.64 µM. SKL1223 interacts with the E-box region of the TXNIP promoter to inhibit TXNIP transcription and related signaling pathways. SKL1223 reduces hepatic glucose output. SKL1223 exerts hypoglycemic effects by regulating the action of glucagon, and modulates blood glucose levels in Streptozotocin ( HY-13753 )-induced and obesity-induced diabetic mice. SKL1223 can be used in the research of type 1 diabetes and type 2 diabetes.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Type 1 Diabetes | Products > Disease Areas > Type 2 Diabetes | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Arrestin

Product Information

• Catalog No.: HY-181335
• CAS No.: 3093938-66-7
• Molecular Formula: C19H15N3O2
• Molecular Weight: 317.34
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source